Agency for Care Effectiveness - ACE

20/08/2025

Patient Champions Making a Difference! 🌟
Meet two inspiring leaders who are helping shape Singapore's healthcare decisions:

Magdalene Chia - A heart disease survivor who leads the Caring Hearts Support Group at NUHCS and serves on the ACE Consumer Panel, bringing patient voices into healthcare decision-making.

Candy Gan - Through typeOne.sg, who gathered patient experiences that informed subsidy recommendations for continuous glucose monitoring (CGM) systems, making diabetes care more accessible.

Their dedication shows how patient voices can create meaningful change in our healthcare system.

Read our impact stories here: https://go.gov.sg/ace-voices-to-impact

19/08/2025

Many people with chronic coronary heart disease (also known as chronic coronary syndrome) take antiplatelet medicines such as aspirin, clopidogrel, or ticagrelor, to lower their risk of heart attack.

Learn the common myths and facts about antiplatelet medicines in our patient education aid: go.gov.sg/acefb267

Singapore Heart Foundation

09/08/2025

Happy National Day! Let’s celebrate the progress made in our 60-year long independence!

At ACE, we remain committed to supporting a healthier, more resilient Singapore through our guidances. Together let’s make Singapore a safer, healthier place!

07/08/2025

Spinal muscular atrophy (SMA) is a genetic condition that affects around 40-60 patients in Singapore. It is caused by changes or mutations in the survival motor neuron 1 (SMN1) gene, leading to a lack of SMN protein. Without this protein, patients experience muscle weakness and wasting, with symptoms such as breathing difficulties and loss of motor function. Patients with severe forms of SMA also have reduced life expectancy.

Dr Jocelyn Lim, a paediatric neurologist at KK Women’s and Children’s Hospital, shared that treatments for SMA are effective but their high costs put them out of reach for many patients. Hence, it is important to make at least one of the three available SMA treatments affordable through subsidies, to ensure more patients can receive appropriate care.

Dr Lim contributed her clinical expertise to ACE’s evaluation of SMA therapies, which informed the MOH Drug Advisory Committee’s recommendation to list risdiplam on the Medication Assistance Fund (MAF). Risdiplam is an orally administered medicine that helps the body make more SMN protein. It is subsidised for treating children and adults with SMA who meet certain clinical criteria. Through Dr Lim’s contributions to the evaluation of SMA therapies, patients now have greater access to a clinically proven and cost-effective treatment.
From October 2025, MediShield Life will also expand coverage to include risdiplam for treating SMA. This will further improve treatment affordability and ensure appropriate care for patients.

Read ACE’s Guidance on risdiplam here👇
https://go.gov.sg/aceli362

01/08/2025

💡Did you know? Lung cancer is one of the most common cancers in Singapore, with around 1,600 diagnoses every year.

Lung cancer isn’t a single disease — it varies depending on the cells affected, and different genetic mutations require different treatments. Over the last 5 years, ACE has reviewed a growing number of treatments to better support patients.
Learn more about treatment options and support available for patients and caregivers 👇
https://go.gov.sg/aceli359 , https://go.gov.sg/acefb264
https://go.gov.sg/aceli360 , https://go.gov.sg/acefb265
https://go.gov.sg/aceli361 , https://go.gov.sg/acefb266

31/07/2025

The Agency for Care Effectiveness (ACE) is Singapore’s the national health technology assessment (HTA) and clinical guidance agency.

We support providers, patients, and payers in making better-informed decisions to improve patient outcomes and healthcare value care in Singapore.

Learn more about what we do:
https://youtu.be/WSC2uE9IevE

Learn more about what we do at ACE that helps make the healthcare system in Singapore more sustainable.

28/07/2025

Did you know? Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease globally.

HCV has been called the “shadow epidemic” as it can remain undetected for years. Most patients with hepatitis C show no symptoms and do not feel different from normal until severe liver damage has occurred. Because hepatitis C is usually asymptomatic, the only way to diagnose the disease is through a blood test.

Hepatitis C can be treated with potent antiviral medicines called direct-acting antiviral agents (DAAs). Recognising the high clinical need for these treatments, ACE conducted health technology assessments and value-based pricing negotiations for DAAs. These assessments were used to inform subsidy recommendations for DAAs by the MOH Drug Advisory Committee, thereby improving treatment affordability and access for patients in Singapore.

25/07/2025

Meet our Principal Analyst, Koh Jen Hun!

At ACE, Jen Hun plays an important role in bringing patient voices into our health technology assessments (HTAs). He works closely with local patient groups and organisations to ensure that ACE’s evaluations are informed by lived experiences— helping policymakers better understand how medical conditions and treatments affect patients, carers, and their families.

Jen Hun also co-develops educational resources with local patient groups to support patients better understand their conditions and treatment options.
Swipe to learn how he bridges the gap between science and people — and what drives his commitment to patient engagement.

22/07/2025

📢 Attention! Registration now open!

Join us at the Appropriate and Value-Based Care (AVBC) Conference 2025—a national platform to explore how we’re Maximising Value for All across Singapore’s health system.

Secure your spot* today: go.gov.sg/avbcconf25

*Pending CME/CPE accreditation.

15/07/2025

Hear from Singapore’s Ministry of Health at HTAsiaLink Conference 2025. Join us for an opening address by Minister of State (Ministry of Health, Singapore) Mdm Rahayu Mahzam, and a keynote by Director-General of Health Prof Kenneth Mak, as they share Singapore’s journey towards value-based care.

View the full speaker lineup here: go.gov.sg/acefb263

04/07/2025

Three impactful plenaries await at the 12th HTAsiaLink Conference 2025. From diverse healthcare perspectives to future possibilities with health technology assessment, each session promises insights that will transform healthcare decisions in Asia.

View the full programme here: go.gov.sg/acefb262